Dasatinib: A Senolytic Drug for Healthspan and Longevity

Aging is accompanied by an increase in senescent cells—cells that no longer divide but remain metabolically active, secreting inflammatory compounds that contribute to age-related diseases. Recent research has identified a class of drugs called senolytics that can selectively eliminate these problematic cells. Among these, dasatinib has emerged as a particularly promising compound with potential longevity benefits, especially when combined with natural compounds like quercetin.

What is Dasatinib?

Dasatinib is an FDA-approved tyrosine kinase inhibitor originally developed for treating myeloid leukemia³. However, its potential extends far beyond cancer treatment. Research has revealed dasatinib’s powerful senolytic properties—the ability to selectively induce death in senescent cells while sparing healthy ones³. This selective elimination can potentially reset the tissue environment to a more youthful state.

The Science Behind Senolytics and Longevity

Cellular senescence is a hallmark of aging, where damaged cells stop dividing but don’t die off naturally. Instead, they accumulate over time and secrete what scientists call the senescence-associated secretory phenotype (SASP)—a collection of inflammatory factors, cytokines, and enzymes that damage surrounding tissues and create chronic inflammation^1,2.

By targeting and eliminating these troublemaking cells, dasatinib addresses one of the root causes of aging rather than merely treating symptoms. This represents a paradigm shift in how we approach age-related decline.

Impressive Results in Animal Studies

The research on dasatinib’s anti-aging effects has yielded remarkable results, particularly when combined with quercetin (a natural flavonoid). This combination, often abbreviated as D+Q, has shown significant benefits in multiple studies:

Dramatic Lifespan Extension

Perhaps most impressively, mice given the dasatinib-quercetin combination at an age equivalent to 75-90 human years lived 36% longer than untreated mice⁵. Not only did they live longer, but they maintained better physical function throughout their extended lives, performing better on tests of walking speed, grip strength, and hanging endurance⁵.

Metabolic Improvements

A 2023 study demonstrated that dasatinib and quercetin significantly improve metabolic function in aged mice. The treatment reduced fasting blood glucose levels, enhanced glucose tolerance, and improved insulin sensitivity^1,2. Additionally, the drug combination reduced plasma triglycerides and enhanced systemic lipid tolerance, suggesting comprehensive metabolic benefits^1,2.

Reduced Inflammation in Adipose Tissue

One of the most consistent findings has been D+Q’s ability to attenuate inflammation in adipose (fat) tissue. The treatment suppressed age-related increases in pro-inflammatory genes and reduced the infiltration of immune cells like T cells and macrophages in fat tissue^1,2. This is particularly significant because adipose inflammation is a key contributor to insulin resistance and metabolic disease with age.

Prevention of Disc Degeneration

Chronic back pain affects millions of elderly individuals, often due to intervertebral disc degeneration. Long-term weekly dosing of dasatinib and quercetin was found to significantly slow disc degeneration in mice⁴. Interestingly, the benefits were greater when treatment started earlier in adult life, suggesting that proactive intervention might be more effective than waiting until significant degeneration has occurred⁴.

Mechanisms of Action

Dasatinib appears to work by targeting specific survival pathways that senescent cells rely on to avoid apoptosis (programmed cell death). When combined with quercetin, which targets complementary pathways including BCL-2, insulin/IGF-1, and HIF-1α networks, the combination becomes particularly effective³.

The senolytic activity results in:

• Reduced expression of senescence markers (p16, p21, SA-β-gal)
• Decreased inflammatory SASP factors (TNF-α, IL-1β, IL-6, etc.)
• Diminished immune cell infiltration in tissues
• Improved tissue function and regenerative capacity

Human Studies and Future Prospects

While animal studies show remarkable promise, human research is still in early stages. A Phase I pilot study administered dasatinib and quercetin to 19 participants for 6 months, measuring effects on DNA methylation patterns—biological markers of aging⁶. Interestingly, researchers observed changes in epigenetic age markers and telomere length, though the implications of these changes require further investigation⁶.

A subsequent study is evaluating dasatinib and quercetin combined with fisetin (another senolytic compound), aiming to establish safety, efficacy, and optimal dosing regimens^6,7. Researchers hypothesize that this combination might effectively decelerate epigenetic biological aging, potentially extending both lifespan and healthspan⁶.

Considerations and Limitations

Despite the promising results, several important questions remain:

• What is the optimal dosing strategy—frequent or intermittent administration?
• At what age should treatment ideally begin?
• Are there long-term side effects from eliminating senescent cells, which may serve some beneficial functions?
• How do results in mice translate to humans with our much longer lifespans?

Conclusion

Dasatinib represents one of the most promising senolytic compounds currently under investigation for extending healthspan and potentially lifespan. When combined with quercetin, it shows remarkable ability to clear senescent cells, reduce inflammation, improve metabolic function, and slow age-related tissue degeneration.

While we await more definitive human studies, the consistent benefits across multiple tissues and physiological systems in animal models suggest that dasatinib may eventually become an important component of anti-aging interventions. By addressing one of the fundamental mechanisms of aging—cellular senescence—this approach offers hope for not just extending life, but extending healthy, functional life.

The next decade of research will be crucial in determining whether dasatinib and other senolytics can fulfill their promise as revolutionary tools for combating age-related decline and disease.

Citations:

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC9924942/
2. https://onlinelibrary.wiley.com/doi/10.1111/acel.13767
3. https://cdn.clinicaltrials.gov/large-docs/34/NCT04313634/Prot_SAP_000.pdf
4. https://www.fightaging.org/archives/2021/09/long-term-weekly-dosage-of-senolytic-dasatinib-and-quercetin-reduces-disc-degeneration-in-mice/
5. https://www.nextbigfuture.com/2018/10/mice-given-dasatinib-quercitin-lived-36-longer-and-in-better-health.html
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10929829/
7. https://optimise.mfm.au/research/slowing-ageing-with-senolytics/
8. https://www.aging-us.com/news-room/A-Longitudinal-Study-on-Dasatinib-Quercetin-and-Fisetin-Senolytic-Interventions
9. https://www.aging-us.com/article/205581/text
10. https://longevity.technology/news/avoid-the-use-of-dq-as-a-senolytic-therapy/
11. https://academic.oup.com/biomedgerontology/article/76/6/1144/6126488
12. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00046-4/fulltext
13. https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2023.1212750/full
14. https://myagingtests.com/dasatinib/
15. https://en.longevitywiki.org/wiki/Dasatinib
16. https://www.nature.com/articles/s41536-023-00304-4
17. https://www.lifeextension.com/magazine/2021/2/senolytics
18. https://www.nature.com/articles/s41467-021-25453-2
19. https://www.fightaging.org/archives/2023/09/a-continued-painfully-slow-assessment-of-the-dasatinib-and-quercetin-senolytic-treatment-in-human-trials/
20. https://www.aging-us.com/article/205581
21. https://www.lifespan.io/road-maps/the-rejuvenation-roadmap/scripps-research-institute-dasatinib-and-quercetin
22. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00300-7/fulltext
23. https://pubmed.ncbi.nlm.nih.gov/29988130/
24. https://www.oncotarget.com/article/28049/text/
25. https://academic.oup.com/biomedgerontology/article/78/Supplement_1/53/7199275
26. https://pubmed.ncbi.nlm.nih.gov/29886783/
27. https://www.annualreviews.org/doi/10.1146/annurev-pharmtox-050120-105018
28. https://www.nih.gov/news-events/nih-research-matters/eliminating-senescent-cells-extends-healthy-life-mice
29. https://www.nad.com/news/senolytics-anti-aging-protein-levels
30. https://www.cancer.gov/news-events/cancer-currents-blog/2020/cml-stopping-tki-treatment-improves-quality-of-life
31. https://www.explorationpub.com/Journals/eds/Article/100840
32. https://www.zest.science/blog/senescent-cells—how-to-fight-the-zombie-cells-that-accelerate-aging
33. https://www.naturaleyecare.com/blog/what-causes-accelerated-aging/
34. https://www.fightaging.org/archives/2018/07/senolytics-reduce-age-related-dysfunction-and-extend-remaining-life-span-by-36-following-administration-to-old-mice/
35. https://www.scripps.edu/news-and-events/press-room/2015/20150309agingcell.html
36. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00342-2/abstract
37. https://ascopubs.org/doi/abs/10.1200/JCO.23.01075
38. https://www.fightaging.org/archives/2025/03/results-from-a-small-trial-of-dasatinib-and-quercetin-in-patients-with-mild-cognitive-impairment/
39. https://www.aging-us.com/article/102772/text
40. https://directorsblog.nih.gov/tag/dasatinib/
41. https://joshmitteldorf.scienceblog.com/2017/03/28/senolytics-against-aging-snapshot-of-a-fast-moving-field/